Ra Capital Management, L.p. sold $1.2M of SION
director, owner at Sionna Therapeutics, Inc.. 30,316 shares at an average of $39.61, traded Nov 20, 2025, filed Nov 24, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- 0Share of holdings soldSold 0.4% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.8%, 3m -18.7%, 6m -7.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000547, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -150 | $39.89 | $5,984 | 6,898,929 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -1,235 | $39.89 | $49k | 661,019 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -801 | $39.89 | $32k | 2,205,034 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -947 | $39.89 | $38k | 167,246 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -96 | $40.50 | $3,888 | 6,898,833 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -788 | $40.50 | $32k | 660,231 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -512 | $40.50 | $21k | 2,204,522 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -604 | $40.50 | $24k | 166,642 | Nov 24, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -1,210 | $39.50 | $48k | 6,897,623 | Nov 24, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -9,924 | $39.50 | $392k | 650,307 | Nov 24, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -6,440 | $39.50 | $254k | 2,198,082 | Nov 24, 2025 |
| Nov 21, 2025 | SOpen-market sale Common Stockindirect: See footnotes | -7,609 | $39.50 | $301k | 159,033 | Nov 24, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $3.9M 85,918 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $3.9M 85,918 shares | -3% | |
| 32Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $447k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $5.3M 115,844 shares | -4% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $5.3M 115,844 shares | -4% | |
| 3Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4,493 101 shares | -0% | |
| 3Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4,493 101 shares | -0% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $13M 292,952 shares | -10% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $13M 292,952 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.